AI-Powered Workflow for Automated Case Quality Control (QC) Checks

Manual QC typically audits 5-10% of cases, leaving errors in the remaining 90% to be caught later—or not at all. This workflow deploys a suite of validation agents that run against every case before finalization, checking for data completeness (e.g., missing patient age), coding accuracy (MedDRA/WHO-DD alignment), and narrative consistency. The result is a defensible, automated gate that prevents flawed cases from progressing to regulatory submission.

The largest bottleneck in case processing is the queue for manual QC review, which can add 24-48 hours of delay. Automated QC agents execute in seconds, providing immediate pass/fail status and detailed exception reports. Cases that pass flow directly to finalization and reporting; exceptions are routed to designated remediators with clear instructions. This removes the single largest waiting period from the case lifecycle.

Pharmacovigilance associates spend significant time on rote checks: verifying field formats, confirming code mappings, and cross-referencing narratives against source documents. This workflow encapsulates those rules into configurable validation agents, freeing senior staff for high-value medical review and signal assessment. The cost savings directly translate to handling increased case volume without proportional headcount growth.

Manual QC introduces variability; one reviewer may miss an error another catches. Automated validation applies the ex same business rules to every case, creating a consistent, documented standard. Every check, pass, and fail is logged with a rationale in the audit trail, providing defensible evidence of due diligence during inspections. This systematic approach strengthens compliance posture and reduces findings.

When the QC agent flags an exception—like an inconsistent event date—it doesn't just reject the case. It routes it to a specific queue (e.g., 'Data Entry - Date Corrections') with the source document excerpt, the failed rule, and suggested corrective action appended. This turns a generic 'fix this' task into a guided correction, slashing the mean time to repair (MTTR) and preventing back-and-forth emails.

The workflow's analytics layer tracks exception patterns—identifying, for example, that 30% of coding errors stem from a specific reporter group or source system. This intelligence is fed back to upstream processes: triggering targeted reporter training or prompting an update to the intake form's data validation. This closes the loop from detection to prevention, systematically driving down error rates over time.

This agent executes the first pass of validation against configured business rules (e.g., mandatory fields populated, valid date sequences, seriousness criteria met). It interfaces directly with the case management system (e.g., ARISg, Veeva Safety) to check workflow state and flag cases with missing or contradictory data. Exceptions are routed to a dedicated remediation queue with clear failure annotations.

A specialized NLP agent reviews verbatim terms and drug names, suggesting the most precise MedDRA PT/LLT and WHO-DD codes. It leverages a RAG system over historical coding decisions and dictionary hierarchies to ensure consistency. Low-confidence suggestions are escalated to human coders via an integrated review interface, creating a continuous feedback loop that improves the agent's precision over time.

This agent performs a cross-field coherence check, ensuring the auto-generated or manually entered case narrative logically aligns with the structured data (e.g., patient age, drug dose, event timeline). It uses an LLM to identify contradictions, implausible sequences, or missing chronology, generating alerts for medical review. This step is critical for preventing regulatory queries and ensuring case narratives are defensible.

The central workflow engine (e.g., LangGraph) manages the state of all cases flowing through QC. It routes failed cases based on error type and severity to the appropriate remediation queue—Data Entry, Medical Coding, or Medical Review. It enforces SLAs, escalates aging items, and only releases cases back to the main workflow after all exceptions are resolved and re-validated by the relevant agent.

Every agent action, validation result, and routing decision is logged to an immutable audit trail linked to the case. This layer provides the explainability required for regulatory inspection, showing the precise rules applied and the rationale for any flags. It integrates with quality management systems (QMS) to automatically log critical deviations for investigation, closing the compliance loop.

The agent suite does not replace the core safety database. Instead, it operates as a middleware layer via secure APIs (REST, SOAP) to pull cases in a 'Ready for QC' state and push back status updates and annotations. This design minimizes disruption, allowing phased rollout. Key integrations are with case processing (Argus, Safety), document management (Veeva Vault), and reporting systems for E2B generation.

Primary Driver: Eliminate manual QC bottlenecks that delay case finalization and risk reporting deadlines. Key Benefit: Achieves 100% case coverage without increasing headcount, reducing average case processing time by 30-50%. Implementation Role: Defines the business rules, validation logic, and acceptable confidence thresholds for the automated agents. Owns the exception queue and oversees the remediation workflow for flagged cases.

Primary Driver: Integrate a scalable, maintainable automation layer into the legacy safety database (e.g., ARISg, Argus) without disrupting existing workflows. Key Benefit: Creates a modular orchestration framework (using LangGraph or similar) that is audit-ready and can be extended to other PV processes. Implementation Role: Designs the API integrations, data pipelines, and agent state management. Ensures the system logs all decisions for traceability and can be rolled out in phased pilots.

Primary Driver: Strengthen data integrity and ensure the automated workflow is defensible to regulators (FDA, EMA). Key Benefit: Transforms QC from a retrospective audit to a continuous, embedded control, providing a complete audit trail for every case. Implementation Role: Approves the validation strategy for the AI agents, defines the escalation paths for low-confidence decisions, and ensures the workflow aligns with ICH GCP and GVP guidelines.

Primary Driver: Reduce repetitive, low-value validation tasks to focus on complex medical assessment and causality judgment. Key Benefit: Agents pre-validate data completeness, suggest MedDRA/WHO-DD codes, and check narrative consistency, allowing reviewers to focus on high-value exceptions. Implementation Role: Provides ground-truth feedback during agent training, reviews and corrects the exception queue, and refines the rule sets based on emerging product profiles.

Primary Driver: Achieve operational leverage and convert fixed QC labor costs into variable, scalable automation. Key Benefit: Directly reduces cost-per-case and protects against volume spikes without proportional headcount increases. Creates capacity for teams to handle more complex products or higher case volumes. Implementation Role: Funds the build, measures ROI based on FTEs redeployed or avoided, and tracks metrics like case throughput and QC cycle time.

Primary Driver: Ensure consistent data quality and process adherence across CROs and licensing partners. Key Benefit: Provides a standardized, transparent QC layer that can be applied to inbound case data from any partner, reducing reconciliation effort and contractual risk. Implementation Role: Defines the data exchange protocols for the QC workflow's outputs (e.g., exception reports) and integrates the system into partner governance dashboards.